Vol. 23 No. 3 (2019)
CORONARY ARTERY DISEASES

Association between genetic determinants of clopidogel metabolism and clinical cardiovascular risk indicators in Buryat patients

PDF (Русский)
  • E. Zelenskaya,
  • K. Nikolaev,
  • O. Donirova,
  • V. Altayev,
  • K. Protasov,
  • E. Voronina,
  • G. Lifshits
E. Zelenskaya
Institute of Chemical Biology and Fundamental Medicine, Novosibirsk
Bio
K. Nikolaev
Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Research Institute of Therapy and Preventive Medicine, Novosibirsk
O. Donirova
N.А. Semashko Republican Clinical Hospital, Ulan-Ude
V. Altayev
N.А. Semashko Republican Clinical Hospital, Ulan-Ude
K. Protasov
Irkutsk State Medical Academy of Postgraduate Education, Irkutsk
E. Voronina
Institute of Chemical Biology and Fundamental Medicine, Novosibirsk
G. Lifshits
Institute of Chemical Biology and Fundamental Medicine, Novosibirsk
DOI: https://doi.org/10.21688/1681-3472-2019-3-39-46

Published 2019-11-27

Keywords

  • acute coronary syndrome,
  • Buryats,
  • clopidogrel,
  • coronary stenting,
  • CYP2C19,
  • ethnic characteristics,
  • VEGFR-2
    • ...More
    Less

How to Cite

Zelenskaya, E., Nikolaev, K., Donirova, O., Altayev, V., Protasov, K., Voronina, E., & Lifshits, G. (2019). Association between genetic determinants of clopidogel metabolism and clinical cardiovascular risk indicators in Buryat patients. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 23(3), 39–46. https://doi.org/10.21688/1681-3472-2019-3-39-46

Copyright (c) 2019 Zelenskaya E. M., Nikolaev K. Y., Donirova O. S., Altayev V. D., Protasov K. V., Voronina E. N., Lifshits G. I.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Background. In some patients, the metabolism of clopidogrel is altered because of the presence of polymorphic variants rs4244285 (* 2), rs4986893 (* 3) and rs12248560 (* 17) in the CYP2C19 gene. There is also evidence of decreased efficacy of clopidogrel in individuals with the T/T genotype in the variant rs2305948 of the VEGFR-2 gene. Nevertheless, this medication is used widely in Russia due to the availability of generic anticoagulants.
Aim. To assess the prevalence of the following polymorphic variants of CYP2C19: rs4244285 (* 2), rs4986893 (* 3) and rs12248560 (* 17); assess the prevalence of the rs2305948 variant of VEGFR-2, and determine cardiovascular risk factors in patients of Buryat nationality.
Methods. The study included 113 patients of Buryat nationality who underwent coronary stent placement due to acute coronary syndrome. Patients were stratified by the presence of the following alleles: CYP2C19 * 2, *3, *17 and VEGFR-2 rs2305948. The following laboratory parameters were measured for all patients: blood glucose, lipid spectrum, creatinine, and glomerular filtration rate. The severity of coronary atherosclerosis was evaluated.
Results. The frequencies of the alleles and halotypes (CYP2C19 * 2, * 3 and *17) were determined. An association between the carriage of the C/C genotype in rs2305948 and a <60 ml/min/1.73 m2 decrease in glomerular filtration rate (χ2 = 4.185, p = 0.032) were found. Additionally, the C/C genotype in rs2305948 was associated with higher blood pressure (χ2 = 12.593, p = 0.001). For men, we identified a positive correlation between the rs2305948 C/C allele and the number of significant coronary stenoses (R = 0.227, p < 0.05).
Conclusion. Among Buryat patients with acute coronary syndrome and percutaneous coronary intervention, the CYP2C19*2,*3 polymorphic variants were associated with a 46.0% decrease in the metabolic rate for clopidogrel. Furthermore, we identified several associations between the C/C genotype in the rs2305948 variant of VEGFR-2 with a number of cardiovascular risk factors.

Received 2 September 2019. Revised 24 October 2019. Accepted 30 October 2019.

Funding: The study did not have sponsorship.

Conflict of interest: Authors declare no conflict of interest.

Author contributions
Conception and study design: V.D. Altayev, K.V. Protasov, G.I. Lifshits
Data collection and analysis: Е.М. Zelenskaya, K.Y. Nikolaev, O.S. Donirova, V.D. Altayev, K.V. Protasov, E.N. Voronina, G.I. Lifshits
Drafting the article: Е.М. Zelenskaya
Critical revision of the article: Е.М. Zelenskaya
Final approval of the version to be published: Е.М. Zelenskaya, K.Y. Nikolaev, O.S. Donirova, V.D. Altayev, K.V. Protasov, E.N. Voronina, G.I. Lifshits

PDF (Русский)

References

  1. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011;10(6):7-122. https://doi.org/10.15829/1560-4071-2018-6-7-122 [Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2011;10(6):7-122. (In Russ.) https://doi.org/10.15829/1560-4071-2018-6-7-122]
  2. Roffi M., Patrono C., Collet J.-P., Mueller C., Valgimigli M., Andreotti F., Bax J.J., Borger M.A., Brotons C., Chew D.P., Gencer B., Hasenfuss G., Kjeldsen K., Lancellotti P., Landmesser U., Mehilli J., Mukherjee D., Storey R.F., Windecker S.; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. PMID: 26320110. https://doi.org/10.1093/eurheartj/ehv320
  3. Тома официальной публикации итогов Всероссийской переписи населения 2010 года. Том 4. Национальный состав и владение языками, гражданство: 742-845. Режим доступа: http://www.gks.ru/free_doc/new_site/perepis2010/croc/perepis_itogi1612.htm. Дата обращения: 21.06.2019. [The volume of the official publication of the 2010 All-Russian Population Census. Volume 4. National composition and language proficiency, citizenship: 742-845]
  4. Китаева Е.Ю., Шпрах В.В., Мирзаев К.Б., Рыжикова К.А., Шуев Г.Н., Созаева Ж.А., Пименова Ю.А., Когай В.В., Сычев Д.А. Частота полиморфизмов генов CYP2C19 и ABCB1, ассоциированных с изменением антиагрегантного действия клопидогрела, у русских и бурят. Сибирское медицинское обозрение. 2018;(3):43-50. https://doi.org/10.20333/2500136-2018-3-43-50 [Kitaeva E.Y., Shprakh V.V., Mirzaev K.B., Ryzhikova K.A., Shuev G.N., Sozaeva Zh.A., Pimenova Y.A., Kogay V.V., Sychev D.A. The frequency of CYP2C19 and ABCB1 polymorphisms associated with a change in the antiplatelet effect of clopidogrel is in Russians and Buryats. Siberian Medical Review. 2018;(3):43-50. (In Russ.) https://doi.org/10.20333/2500136-2018-3-43-50]
  5. Zhang L., Zhang Y.Q., Han X., Zhang Z.T., Zhang Z.Q. Association of VEGFR-2 gene polymorphisms with clopidogrel resistance in patients with coronary heart disease. Am J Ther. 2016;23(6):e1663-e1670. PMID: 25738571. https://doi.org/10.1097/MJT.0000000000000231
  6. Belozerceva L.A., Voronina E.N., Kokh N.V., Tsvetovskay G.A., Momot A.P., Lifshits G.I., Filipenko M.L., Shevela A.I., Vlasov V.V. Personalized approach of medication by indirect anticoagulants tailored to the patient russian context: what are the prospects? EPMA J. 2012;3(1):3-10. PMID: 23016735, PMCID: PMC3492156. https://doi.org/10.1186/1878-5085-3-10
  7. Tang H., Quertermous T., Rodriguez B., Kardia S.L.R., Zhu X., Brown A., Pankow J.S., Province M.A., Hunt S.C., Boerwinkle E., Schork N.J., Risch N.J. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet. 2005;(76):268-75. PMCID: PMC1196372, PMID: 15625622. https://doi.org/10.1086/427888
  8. Daoulah A., Elkhateeb O.E., Nasseri S.A., Al-Murayeh M., Al-Kaabi S., Lotfi A., Alama M.N., Al-Faifi S.M., Haddara M., Dixon C.M., Alzahrani I.S., Alghamdi A.A., Ahmed W., Fathey A., Haq E., Alsheikh-Ali A.A. Socioeconomic factors and severity of coronary artery disease in patients undergoing coronary angiography: a multicentre study of Arabian Gulf States. Open Cardiovasc Med J. 2017;11:47-57. PMID: 28553410, PMCID: PMC5427707. https://doi.org/10.2174/1874192401711010047
  9. Мирзаев К.Б., Барбараш О.Л., Ганюков В.И., Кочергин Н.А., Апарцин К.А., Сараева Н.О., Горохова А.В., Николаев К.Ю., Батуева К.Ю., Конова О.Д., Гришина Е.А., Рыжикова К.А., Созаева Ж.А., Гиляров М.Ю., Андреев Д.А., Лифшиц Г.И., Сычев Д.А. Частота носительства клинически значимых аллелей гена CYP2C19 у пациентов с острым коронарным синдромом из Центральной, Восточной, Северной Сибири и Московского региона. Креативная кардиология. 2017;11(1):8-19. https://doi.org/10.15275/kreatkard.2017.01.02 [Mirzaev K.B., Barbarash O.L., Ganyukov V.I., Kochergin N.A., Apartsin K.A., Saraeva N.O., Gorohova A.V., Nikolaev K.Yu., Batueva K.Yu., Konova O.D., Grishina E.A., Ryzhikova K.A., Sozaeva Zh.A., Gilyarov M.Yu., Andreev D.A., Lifshits G.I., Sychev D.A. The frequency of CYP2C19 allelic variants in patients with acute coronary syndrome in central, eastern, northern Siberia and Moscow region. Kreativnaya kardiologiya = Creative Cardiology. 2017;11(1):8-19. (In Russ.) https://doi.org/10.15275/kreatkard.2017.01.02]
  10. Fricke-Galindo I., Céspedes-Garro C., Rodrigues-Soares F., Naranjo M.E., Delgado Á., de Andrés F., López-López M., Peñas-Lledó E., LLerena A1. Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations. Pharmacogenomics J. 2016;16(2):113-23. PMID: 26503820. https://doi.org/10.1038/tpj.2015.70.
  11. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(6):7-122. https://doi.org/10.15829/1560-4071-2018-6-7-122. [Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russ.) http://dx.doi.org/10.15829/1560-4071-2018-6-7-122]
  12. Николаев К.Ю., Урванцева И.А., Батуева К.Ю., Апарцын К.А., Горохова А.В., Ганюков В.И., Кочергин Н.А., Зеленская Е.М., Лифшиц Г.И. Региональные аспекты связей полиморфизма гена VEGFR2 с атеросклерозом коронарных артерий при остром коронарном синдроме. Российский кардиологический журнал. 2017;(10):61-65. https://doi.org/10.15829/1560-4071-2017-10-61-65 [Nikolaev K.Y., Urvantseva I.A., Batueva K.Y., Apartsin К.A., Gorokhova А.V., Ganyukov V.I., Kochergin N.А., Zelenskaya Е.M., Lifshits G.I. Regional aspects of the links of VEGFR2 gene polymorphism with coronary arteries atherosclerosis in acute coronary syndrome. Russian Journal of Cardiology. 2017;10(150):61-65. (In Russ.) https://doi.org/10.15829/1560-4071-2017-10-61-65]
  13. Liu D., Song J., Ji X., Liu Z., Cong M., Hu B. Association of genetic polymorphisms on VEGFA and VEGFR2 with risk of coronary heart disease. Medicine (Baltimore). 2016;95(19):e3413. PMID: 27175642, PMCID: PMC4902484. https://doi.org/10.1097/MD.0000000000003413
  14. Berezin A.E. Endothelial progenitor cells dysfunction and impaired tissue reparation: The missed link in diabetes mellitus development. Diabetes & Metabolic Syndrome. 2017;11(3):215-220. PMID: 27578620. https://doi.org/10.1016/j.dsx.2016.08.007
  15. Кнауэр Н.Ю., Лифшиц Г.И., Воронина Е.Н., Коледа Н.В., Гуськова Е.В. Информативность генетических маркеров для оптимизации персонализированной терапии клопидогрелом. Кардиология. 2013;53(8):72-75. [Knauer N.Yu., Lifshits G.I., Voronina E.N., Koleda N.V., Guskova E.V. The information content of genetic markers to optimize personalized therapy with clopidogrel. Kardiologiya. 2013;53(8):72-75. (In Russ.)]